Please login to the form below

Not currently logged in
Email:
Password:

Evotec enters new alliance with Genentech

Evotec and Genentech have formed a new integrated drug discovery alliance to support research into novel small molecule therapeutics

Evotec has announced today that it has formed a new alliance with Genentech (owned by Roche) to support Genentech's research to discover novel small molecule therapeutics.

Said Dr Werner Lanthaler, Evotec's CEO: "We are proud that Genentech, one of the premier biopharmaceutical companies worldwide, has selected Evotec's scientists and innovative drug discovery platform to support its research efforts. We look forward to working closely with Genentech's scientists and achieving success together."

The collaboration includes assay development and high throughput screening, medicinal chemistry and structural biology. Terms for the collaboration have not been disclosed.

Roche (one of several pharma companies working jointly with Evotec to develop its pipeline of products) already has several collaborative research areas in place, including one for product development in treatment-resistant depression and another to jointly discover and develop compounds against a target for CNS diseases and other indications.

Evotec is due to report its financial/performance results for the first quarter of 2010 on Wednesday May 12.

10th May 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics